Exiqon

Danish life sciences and diagnostics company Exiqon plans to use a DKK 12 million ($2.1 million), five-year grant from the Danish Technology Foundation to develop next-generation sequencing and bioinformatics capabilities for precision medicine.

NEW YORK (Genomeweb News) – Exiqon announced today that its second quarter revenues increased 15 percent year over year as it significantly trimmed its net loss for the period.

Exiqon and Asuragen said this week that they have signed a service center agreement that allows Asuragen to provide real-time PCR services based on Exiqon's MiRcury LNA Universal RT microRNA PCR products.

NEW YORK (GenomeWeb News) – Exiqon and Asuragen announced today the signing of a service center agreement allowing Asuragen to offer real-time PCR services based on Exiqon's miRcury LNA Universal RT-microRNA PCR products.

NEW YORK (GenomeWeb News) – Partners in Denmark have joined to embark on a €5.2 million ($6.8 million) personalized cancer diagnostic project.

NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics company Exiqon said today that revenues in the first quarter rose 33 percent year over year on the strength of its research products.

Exiqon has introduced the third generation of its microRNA qPCR focus panel for preclinical toxicology research.

This week, Affymetrix and BioDiscovery jointly launched Nexus for OncoScan, a tool based on BioDiscovery's Nexus Copy Number software for customers of Affymetrix's OncoScan FFPE Express 2.0 Service, which generates whole genome copy number data f

Swift Biosciences recently launched myT KRAS, the third product in its myT Primer menu of reagents to detect cancer mutations.

Exiqon has launched miRSearch v 2.0, an online search tool for microRNA information and related miRNA and long, non-coding RNA information.
The tool can be found here.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.